表紙
市場調查報告書
商品編碼
1040476

高血壓性心臟疾病市場(2021年∼2027年)

Hypertensive Heart Disease Market 2021-2027

出版日期: | 出版商: Orion Market Research Pvt Ltd | 英文 | 商品交期: 2-3個工作天內

價格
  • 全貌
  • 簡介
  • 目錄
簡介

全球高血壓性心臟疾病的市場規模,在預測期間內預計以3.5%大幅度的年複合成長率成長。帶動這個市場的主要原因,有心血管疾病的盛行率上升,政府為了研究開發新藥投入莫大的醫療費等。

本報告提供全球高血壓性心臟疾病市場調查,市場概要,市場的推動因素與阻礙因素分析,COVID-19的影響,市場機會,各診斷、治療方法、地區的市場分析,主要企業的簡介等系統性資訊。

目錄

第1章 報告概要

第2章 市場概要與洞察

  • 調查範圍
  • 分析師的洞察和目前市場趨勢

第3章 競爭情形

  • 主要企業分析
    • 概要
    • 財務分析
    • SWOT分析
    • 最近的開發
  • 主要策略分析
  • COVID-19對主要企業的影響

第4章 市場決策要素

  • 促進因素
  • 阻礙因素
  • 市場機會

第5章 市場細分化

  • 高血壓性心臟疾病的全球市場:各診斷
    • 心電圖
    • 心臟超音波圖
    • 冠動脈攝影術
    • 其他(胸部X光)
  • 高血壓性心臟疾病的全球市場:各治療法
    • 藥物
    • 手術

第6章 地區分析

  • 北美
    • 美國
    • 加拿大
  • 歐洲
    • 英國
    • 德國
    • 義大利
    • 西班牙
    • 法國
    • 其他歐洲
  • 亞太地區
    • 中國
    • 印度
    • 日本
    • 韓國
    • 其他亞太地區
  • 其他地區
    • 南美
    • 中東、非洲

第7章 企業簡介

  • Abbott Laboratories
  • AstraZeneca PLC
  • Actelion Pharmaceuticals Ltd.
  • Boehringer Ingelheim International GmbH
  • Bayer AG
  • Eiger Biopharmaceuticals, Inc.,
  • Daiichi Sankyo Co., Ltd.
  • Gilead Sciences, Inc.
  • GlaxoSmithKline PLC
  • F. Hoffmann-La Roche Ltd.
  • Johnson & Johnson Services, Inc.
  • Lupin Pharmaceuticals, Inc.
  • Merck KGaA
  • Novartis AG
  • Pfizer Inc.
  • Sanofi SA
  • Sun Pharmaceutical Industries Ltd.
  • Takeda Pharmaceutical Co. Ltd.
  • United Therapeutics Corp.
  • Northern Therapeutics Inc.
目錄
Product Code: OMR2024027

Global Hypertensive Heart Diseases Market Size, Share &Trends Analysis Report By Diagnosis (Electrocardiogram, Echocardiogram, Coronary Angiography, Others) By Therapeutic (Drugs, and Surgery) Forecast, 2021-2027

The global hypertensive heart diseases market is anticipated to grow at a substantial CAGR of 3.5% during the forecast period. The rising prevalence of cardiovascular disease is the key factor driving the market growth. According to WHO, every year around 17.9 million people die due to cardiovascular diseases, which is an estimated 32% of all deaths globally. The huge healthcare expenditure by the Government for the R&D of new drugs also playing a major role in the development of the market. For instance, from 2017 to 2018, medical and health R&D spending in the US grew by 6.4%, reaching $194.2 billion. In the same year, in the US, around $2.3 billion on medical and health R&D were invested by govt foundations, state and local governments invested $2.1 billion, and voluntary health associations and professional societies invested $1.5 billion (overall, 3.1%). Furthermore, the high cost associated with the treatment of cardiovascular diseases is the factor that may be projected to hamper the market growth. In 2010, the global cost of cardiovascular diseases was $863 million, which is expected to reach nearly $1,044 billion by 2030.

The global hypertensive heart diseases market is segmented based on diagnosis and therapeutics. Based on the diagnosis, the market is sub-segmented into electrocardiogram, echocardiogram, coronary angiography, and others (chest x-ray). Based on therapeutics, the global hypertensive heart diseases market is classified into drugs and surgery. The drug segment is further categorized into thiazide diuretics beta-blockers, angiotensin-converting enzyme (ACE) inhibitors, angiotensin II receptor blockers (ARB), calcium channel blockers, and others (renin inhibitors). Similarly, the surgery segment is further classified into coronary artery bypass surgery, transmyocardial laser revascularization, and heart transplant. Among the therapeutic segment, the surgery sub-segment is projected to grow at faster CAGR during the forecast period owing to the increasing surgical transplant procedure due to the rising prevalence of heart failures

Geographically market is segmented into North America, Europe, Asia Pacific, and the Rest of the World. Asia-Pacific is projected to be the fastest-growing region in the global hypertensive heart diseases market. China, India, Japan are the major contributors to the market growth. The growing awareness programs regarding hypertensive heart diseases in the major economies of the Asia-Pacific, growing awareness regarding treatments and diagnosis of heart diseases, and rising expenditure on R&D are the major factors driving the growth of the market in the region. Whereas, North America dominated the market, and it is expected to hold a significant share in the market during the forecast period. The high prevalence of cardiovascular diseases especially in the US, development in healthcare expenditure, technology advancements, and presence of key players operating in the hypertensive heart diseases market are the prominent factors boosting the growth of the market.

Furthermore, the major players operating in the global hypertensive heart diseases market are Abbott Laboratories, AstraZeneca PLC, Bayer AG, Boehringer Ingelheim International GmbH, Johnson &Johnson Ltd., Merck KGaA, Novartis AG, Pfizer Inc., and Sanofi SA, among others.

Research Methodology

The market study of the global hypertensive heart diseases market is incorporated by extensive primary and secondary research conducted by the research team at OMR Secondary research has been conducted to refine the available data to break down the market into various segments, derive total market size, market forecast, and growth rate. Different approaches have been worked on to derive the market value and market growth rate. Our team collects facts and data related to the market from different geography to provide a better regional outlook. In the report, the country-level analysis is provided by analyzing various regional players, regional tax laws and policies, consumer behavior, and macro-economic factors. Numbers extracted from secondary research have been authenticated by conducting proper primary research. It includes tracking down key people from the industry and interviewing them to validate the data. This enables our analyst to derive the closest possible figures without any major deviations in the actual number. Our analysts try to contact as many executives as possible, managers, key opinion leaders, and industry experts. Primary research brings authenticity to our reports.

Secondary Sources Include

Financial reports of companies involved in the market

Whitepapers, research papers, and news blogs

Company websites and their product catalog

The report provides an in-depth analysis of market size, intended quality of the service preferred by consumers. The report will serve as a source for a 360-degree analysis of the market thoroughly integrating different models.

Market Segmentation

Global Hypertensive Heart Diseases Market Research and Analysis by Diagnosis

Global Hypertensive Heart Diseases Market Research and Analysis by Therapeutics

The Report Covers

Comprehensive research methodology of the global hypertensive heart diseases market

This report also includes a detailed and extensive market overview with key analyst insights

An exhaustive analysis of macro and micro factors influencing the market guided by key recommendations

Analysis of regional regulations and other government policies impacting the global hypertensive heart diseases market

Insights about market determinants that are stimulating the global hypertensive heart diseases market

Detailed and extensive market segments with the regional distribution of forecasted revenues

Extensive profiles and recent developments of market players

Table of Contents

1. Report Summary

  • Current Industry Analysis and Growth Potential Outlook
  • Impact of COVID-19 on the Global Hypertensive Heart Disease Industry
  • Recovery Scenario of Global Hypertensive Heart Disease Industry
  • 1.1. Research Methods and Tools
  • 1.2. Market Breakdown
    • 1.2.1. By Segments
    • 1.2.2. By Geography

2. Market Overview and Insights

  • 2.1. Scope of the Report
  • 2.2. Analyst Insight & Current Market Trends
    • 2.2.1. Key Findings
    • 2.2.2. Recommendations
    • 2.2.3. Conclusion

3. Competitive Landscape

  • 3.1. Key Company Analysis
    • 3.1.1. Overview
    • 3.1.2. Financial Analysis
    • 3.1.3. SWOT Analysis
    • 3.1.4. Recent Developments
  • 3.2. Key Strategy Analysis
  • 3.3. Impact of COVID-19 on key players

4. Market Determinants

  • 4.1. Motivators
  • 4.2. Restraints
  • 4.3. Opportunities

5. Market Segmentation

  • 5.1. Global Hypertensive Heart Disease Market, ByDiagnosis
    • 5.1.1. Electrocardiogram
    • 5.1.2. Echocardiogram
    • 5.1.3. Coronary Angiography
    • 5.1.4. Others (Chest X-Ray)
  • 5.2. Global Hypertensive Heart Disease Market, ByTherapeutics
    • 5.2.1. Drugs
      • 5.2.1.1. Thiazide Diuretics
      • 5.2.1.2. Beta-Blockers
      • 5.2.1.3. Angiotensin-Converting Enzyme (ACE) Inhibitors
      • 5.2.1.4. Angiotensin II Receptor Blockers (ARB)
      • 5.2.1.5. Calcium Channel Blockers
      • 5.2.1.6. Others (Renin Inhibitors)
    • 5.2.2. Surgery
      • 5.2.2.1. Coronary Artery Bypass Surgery
      • 5.2.2.2. Transmyocardial Laser Revascularization
      • 5.2.2.3. Heart Transplant

6. Regional Analysis

  • 6.1. North America
    • 6.1.1. United States
    • 6.1.2. Canada
  • 6.2. Europe
    • 6.2.1. UK
    • 6.2.2. Germany
    • 6.2.3. Italy
    • 6.2.4. Spain
    • 6.2.5. France
    • 6.2.6. Rest of Europe
  • 6.3. Asia-Pacific
    • 6.3.1. China
    • 6.3.2. India
    • 6.3.3. Japan
    • 6.3.4. South Korea
    • 6.3.5. Rest of Asia-Pacific
  • 6.4. Rest of the World
    • 6.4.1. Latin America
    • 6.4.2. Middle East & Africa

7. Company Profiles

  • 7.1. Abbott Laboratories
  • 7.2. AstraZeneca PLC
  • 7.3. Actelion Pharmaceuticals Ltd.
  • 7.4. Boehringer Ingelheim International GmbH
  • 7.5. Bayer AG
  • 7.6. Eiger Biopharmaceuticals, Inc.,
  • 7.7. Daiichi Sankyo Co., Ltd.
  • 7.8. Gilead Sciences, Inc.
  • 7.9. GlaxoSmithKline PLC
  • 7.10. F. Hoffmann-La Roche Ltd.
  • 7.11. Johnson & Johnson Services, Inc.
  • 7.12. Lupin Pharmaceuticals, Inc.
  • 7.13. Merck KGaA
  • 7.14. Novartis AG
  • 7.15. Pfizer Inc.
  • 7.16. Sanofi SA
  • 7.17. Sun Pharmaceutical Industries Ltd.
  • 7.18. Takeda Pharmaceutical Co. Ltd.
  • 7.19. United Therapeutics Corp.
  • 7.20. Northern Therapeutics Inc.

LIST OF TABLES

  • 1. GLOBAL HYPERTENSIVE HEART DISEASE MARKET RESEARCH AND ANALYSIS BY DIAGNOSIS, 2020-2027 ($ MILLION)
  • 2. GLOBAL ELECTROCARDIOGRAM FOR HYPERTENSIVE HEART DISEASE MARKET RESEARCH AND ANALYSIS BY REGION, 2020-2027 ($ MILLION)
  • 3. GLOBAL ECHOCARDIOGRAMFOR HYPERTENSIVE HEART DISEASE MARKET RESEARCH AND ANALYSIS BY REGION, 2020-2027 ($ MILLION)
  • 4. GLOBAL CORONARY ANGIOGRAPHYFOR HYPERTENSIVE HEART DISEASE MARKET RESEARCH AND ANALYSIS BY REGION, 2020-2027 ($ MILLION)
  • 5. GLOBAL OTHERS (CHEST X-RAY)FOR HYPERTENSIVE HEART DISEASE MARKET RESEARCH AND ANALYSIS BY REGION, 2020-2027 ($ MILLION)
  • 6. GLOBAL HYPERTENSIVE HEART DISEASE MARKET RESEARCH AND ANALYSIS BY THERAPEUTICS, 2020-2027 ($ MILLION)
  • 7. GLOBAL DRUGS FOR HYPERTENSIVE HEART DISEASE MARKET RESEARCH AND ANALYSIS BY REGION, 2020-2027 ($ MILLION)
  • 8. GLOBAL DRUGS FOR HYPERTENSIVE HEART DISEASE MARKET RESEARCH AND ANALYSIS BY TYPE, 2020-2027 ($ MILLION)
  • 9. GLOBAL SURGERY FOR HYPERTENSIVE HEART DISEASE MARKET RESEARCH AND ANALYSIS BY REGION, 2020-2027 ($ MILLION)
  • 10. GLOBAL SURGERY FOR HYPERTENSIVE HEART DISEASE MARKET RESEARCH AND ANALYSIS BY TYPE, 2020-2027 ($ MILLION)
  • 11. NORTH AMERICAN HYPERTENSIVE HEART DISEASE MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2020-2027 ($ MILLION)
  • 12. NORTH AMERICAN HYPERTENSIVE HEART DISEASE MARKET RESEARCH AND ANALYSIS BY DIAGNOSIS,2020-2027 ($ MILLION)
  • 13. NORTH AMERICAN HYPERTENSIVE HEART DISEASE MARKET RESEARCH AND ANALYSIS BYTHERAPEUTICS, 2020-2027 ($ MILLION)
  • 14. EUROPEAN HYPERTENSIVE HEART DISEASE MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2020-2027 ($ MILLION)
  • 15. EUROPEAN HYPERTENSIVE HEART DISEASE MARKET RESEARCH AND ANALYSIS BY DIAGNOSIS, 2020-2027 ($ MILLION)
  • 16. EUROPEAN HYPERTENSIVE HEART DISEASE MARKET RESEARCH AND ANALYSIS BYTHERAPEUTICS, 2020-2027 ($ MILLION)
  • 17. ASIA-PACIFIC HYPERTENSIVE HEART DISEASE MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2020-2027 ($ MILLION)
  • 18. ASIA-PACIFIC HYPERTENSIVE HEART DISEASE MARKET RESEARCH AND ANALYSIS BY DIAGNOSIS, 2020-2027 ($ MILLION)
  • 19. ASIA-PACIFIC HYPERTENSIVE HEART DISEASE MARKET RESEARCH AND ANALYSIS BYTHERAPEUTICS, 2020-2027 ($ MILLION)
  • 20. REST OF THE WORLD HYPERTENSIVE HEART DISEASE MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2020-2027 ($ MILLION)
  • 21. REST OF THE WORLD HYPERTENSIVE HEART DISEASE MARKET RESEARCH AND ANALYSIS BY DIAGNOSIS, 2020-2027 ($ MILLION)
  • 22. REST OF THE WORLD HYPERTENSIVE HEART DISEASE MARKET RESEARCH AND ANALYSIS BY THERAPEUTICS, 2020-2027 ($ MILLION)

LIST OF FIGURES

1. IMPACT OF COVID-19 ON GLOBAL HYPERTENSIVE HEART DISEASE MARKET, 2020-2027 (% MILLION)

2. IMPACT OF COVID-19 ON GLOBAL HYPERTENSIVE HEART DISEASE MARKET BY SEGMENT, 2020-2027 (% MILLION)

  • 3. RECOVERY OF GLOBAL HYPERTENSIVE HEART DISEASE MARKET, 2020-2027 (%)
  • 4. GLOBAL HYPERTENSIVE HEART DISEASE MARKET SHARE BY DIAGNOSIS,2020 VS 2027 (%)
  • 5. GLOBAL HYPERTENSIVE HEART DISEASE MARKET SHARE BY THERAPEUTICS, 2020 VS 2027 (%)
  • 6. GLOBAL HYPERTENSIVE HEART DISEASE MARKET SHARE BY GEOGRAPHY, 2020 VS 2027 (%)
  • 7. GLOBAL ELECTROCARDIOGRAM MARKET SHARE BY REGION, 2020-2027 ($ MILLION)
  • 8. GLOBAL ECHOCARDIOGRAM MARKET SHARE BY REGION, 2020-2027 ($ MILLION)
  • 9. GLOBAL CORONARY ANGIOGRAPHY MARKET SHARE BY REGION, 2020-2027 ($ MILLION)
  • 10. GLOBAL OTHERS (CHEST X-RAY) MARKET SHARE BY REGION, 2020-2027 ($ MILLION)
  • 11. GLOBAL DRUGS FOR HYPERTENSIVE HEART DISEASE MARKET SHARE BY REGION, 2020-2027 ($ MILLION)
  • 12. GLOBAL DRUGS FOR HYPERTENSIVE HEART DISEASE MARKET SHARE BY TYPE, 2020-2027 ($ MILLION)
  • 13. GLOBAL SURGERY FOR HYPERTENSIVE HEART DISEASE SHARE BY REGION, 2020-2027 ($ MILLION)
  • 14. GLOBAL SURGERY FOR HYPERTENSIVE HEART DISEASE SHARE BY TYPE, 2020-2027 ($ MILLION)
  • 15. US HYPERTENSIVE HEART DISEASE MARKET SIZE, 2020-2027 ($ MILLION)
  • 16. CANADA HYPERTENSIVE HEART DISEASE MARKET SIZE, 2020-2027 ($ MILLION)
  • 17. UK HYPERTENSIVE HEART DISEASE MARKET SIZE, 2020-2027 ($ MILLION)
  • 18. FRANCE HYPERTENSIVE HEART DISEASE MARKET SIZE, 2020-2027 ($ MILLION)
  • 19. GERMANY HYPERTENSIVE HEART DISEASE MARKET SIZE, 2020-2027 ($ MILLION)
  • 20. ITALY HYPERTENSIVE HEART DISEASE MARKET SIZE, 2020-2027 ($ MILLION)
  • 21. SPAIN HYPERTENSIVE HEART DISEASE MARKET SIZE, 2020-2027 ($ MILLION)
  • 22. REST OF EUROPE HYPERTENSIVE HEART DISEASE MARKET SIZE, 2020-2027 ($ MILLION)
  • 23. INDIA HYPERTENSIVE HEART DISEASE MARKET SIZE, 2020-2027 ($ MILLION)
  • 24. CHINA HYPERTENSIVE HEART DISEASE MARKET SIZE, 2020-2027 ($ MILLION)
  • 25. JAPAN HYPERTENSIVE HEART DISEASE MARKET SIZE, 2020-2027 ($ MILLION)
  • 26. SOUTH KOREA HYPERTENSIVE HEART DISEASE MARKET SIZE, 2020-2027 ($ MILLION)
  • 27. REST OF ASIA-PACIFIC HYPERTENSIVE HEART DISEASE MARKET SIZE, 2020-2027 ($ MILLION)

28. REST OF THE WORLD HYPERTENSIVE HEART DISEASE MARKET SIZE, 2021-2027($ MILLION